novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

Roche’s cancer drug Rozlytrek scores double approval from FDA

August 16, 2019
Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology

The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …

cannabis-2152604_960_720

Hundreds of patients turn to private cannabis clinics in UK

August 16, 2019
Medical Communications Marijuana, NHS, UK, cannabis, medicinal cannabis, pharma

Hundreds of people have turned to private clinics, in an effort to gain access to medicinal cannabis in the UK, …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

Pfizer recall two batches of migraine drug Relpax

August 16, 2019
Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …

ipos0_l

Regeneron invest $800 million into New York facilities

August 15, 2019
Medical Communications East Greenbush, New York, Regeneron, pharma

Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …

regeneron

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

August 15, 2019
Research and Development Regeneron, evinacumab, pharma, rare disease

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …

lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …

28246711066_52e38bc591_z

Britain call on companies to bid for 24 hour Brexit medicines shipping service contract

August 15, 2019
Business Services, Sales and Marketing UK, brexit, britain, medicines, pharma

The British Government is calling on logistics companies to bid for a £25 million contract to run express freight containers …

FDA approve new drug for treatment-resistant TB

August 15, 2019
Research and Development FDA, TB, US, pharma, pretomanid, tuberculosis

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB). The US regulator gave the go-ahead …

Executive shake-up at Novartis after Zolgensma data scandal

August 14, 2019
Business Services

The AveXis executives that oversaw the marketing application for Zolgensma, the $2.1 million gene therapy at the centre of the …

lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …

janssen_latest_logo_on_sign_closer

Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019
Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …

Aspen Pharmacare to pay £8 million after colluding to rip off NHS

August 14, 2019
Research and Development Addison's disease, Aspen Pharmacare, CMA, NHS, pharma

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment. The …

17096650341_abceee54b5_z

Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years

August 14, 2019
Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health

Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …

25482028522_7a08ece5bb_z1

Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal

August 13, 2019
Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc

Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …

shutterstock_114045100

Making things personal: Roche and personalised medicine

August 13, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, feature, personalised medicine, pharma

Ann Costello, Global Franchise Lead, Centralised Solutions at Roche Diagnostics, discusses the increasing need for a personalised approach to patient …

shutterstock_360472550

MSD teams up with Harvard University to discover novel immune system pathways to fight cancer

August 13, 2019
Manufacturing and Production, Research and Development Cancer, Harvard, MSD, Merck, immuno-oncology, oncology, pharma

A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …

opioid_therapy_credit_-_us_air_force_valerie_monroy

Camurus’ weekly/monthly opioid dependence injection accepted in Scotland for NHS use

August 13, 2019
Manufacturing and Production, Sales and Marketing Camurus, NHS, Scotland, nhs scotland, opioid dependence, opioids, pharma

The Scottish Medicines Consortium (SMC) has announced its acceptance of Buvidal (buprenorphine prolonged-release solution for subcutaneous injection) from Swedish pharma …

bacteria-163711_960_720

Chlamydia vaccine proves safe in Phase 1 trial

August 13, 2019
Manufacturing and Production chlamydia, clinicla trials, infectious diseases, pharma, vaccines

A chlamydia vaccine has shown to be safe in a Phase 1 clinical trial, according to a study published in …

The Gateway to Local Adoption Series

Latest content